ASCO 2020：11项中国研究入选口头分析报告，17项Poster分析报告

受全球新冠疫情因素，月初于5月29日~6月2日在芝加哥出席的美国诊断学都会（ASCO）年都会去年将首次以线上形式筹办，这是目前最大规模的线上盛都会。时至今日，开都会的概要题目公布，共103个sessions，里国一共11项研究成果入选口头报告，17项入选Poster

Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.Session: Breast Cancer—MetastaticAuthor(s): Binghe Xu, Min Yan, Fei Ma, Xi-Chun Hu, Ji Feng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Xiaoyu Zhu, Chunxia Chen, Jianjun ZouAbstract: 1003

吡咯替尼或佩佩替尼加卡培他滨主要用途HER2+前列腺癌前列腺胰脏（PHOEBE）：一项III期随机次测试。

三场：前列腺癌前列腺胰脏

写作者：里国医学科学院的医院徐兵河任教、马飞任教，清华大学所的医院胡夕春任教等

概要号：1003

Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).

Session: Breast Cancer—Local/Regional/Adjuvant

Author(s): XI Wang, Shu-Sen Wang, Heng Huang, Li Cai, Rou-Jun Peng, Li Zhao, Ying Lin, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, Qian-Jun Chen, An-Qin Zhang, Dan-Mei Pang, Fei Xu, Jia J. Huang, Yanxia Shi, Jun Tang, Zhongyu Yuan

Abstract: 507

可开刀三比如说前列腺胰脏标准疗法后卡培他滨延续节拍化学治疗的III期次测试（SYSUCC-001）。

三场：前列腺胰脏—渐进/区域/常规疗法

写作者：里山大学防治里心王树森任教等

概要号：507

Utilizing phenotypic characteristics of metastatic brain tumors to predict the probability of circulating tumor DNA detection from cerebrospinal fluid.Session: New Tools to Combat Old FoesAuthor(s): Meichen Li, Delan Li, Xue Hou, Xiangheng Zhang, Na Wang, Jianzhong Liang, Jing Chen, Kaicheng Wang, Fufeng Wang, Yedan Chen, Xian Zhang, Hua Bao, Xue Wu, Xiaonan Wang, Yang Shao, Likun ChenAbstract: 2507

利用前列腺癌神经的基因型特质来计算肾脏里循环DNA检测的概率: 新工具对抗据闻对手

三场：新工具解决据闻问题

写作者：郭美芹 郭德兰等

概要号: 2507

Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Feng Bi, Shukui Qin, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Zishu Wang, Jieer Ying, Yinying Lu, Zhiqiang Meng, Hongming Pan, Ping Yang, Helong Zhang, Xi Chen, Aibing Xu, Xiufeng Liu, Qiu Meng, Liqing Wu, Feng Chen

Abstract: 4506

罗萨非尼对比索拉非尼作为中后期肝蛋白质胰脏的前沿疗法：一项新开标签、随机、多里心II/III期次测试。

三场：肺肠道胰脏—肺胃、胰脏和绝

写作者：南京大学棱果的医院毕锋任教、里国团结解放军八一的医院秦叔逵任教等

概要号：4506

Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Qiu Li, Shukui Qin, Shanzhi Gu, Xiaoming Chen, Lizhu Lin, Zishu Wang, Aibing Xu, Xi Chen, Cuncai Zhou, Zhenggang Ren, Lin Yang, Li Xu, Yuxian Bai, Lei Chen, Jun Li, Hongming Pan, Bangwei Cao, Weijia Fang, Ping Yan, Chunlei Jin

Abstract: 4507

里国中后期肝胰脏患儿阿帕替尼中卫疗法：一项随机、安慰剂对照、诊断III期研究成果

三场：肺肠道胰脏—肺胃、胰脏和绝

写作者：里国团结解放军八一的医院秦叔逵任教、南京大学棱果的医院郭秋任教等

概要号：4507

A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2.

Session: Gynecologic Cancer

Author(s): Rongyu Zang, Jianqing Zhu, Tingyan Shi, Jihong Liu, Dongsheng Tu, Sheng Yin, Rong Jiang, Ping Zhang, Huixun Jia, Yuting Luan, Yuqin Zhang, Xiaojun Chen, Xiao Huang, Wenjuan Tian, Wen Gao, Yanling Feng, Huijuan Yang, Xi Cheng, Yulang Cai

Abstract: 6001

中后期罹患性卵巢胰脏二次蛋白质减灭术的一项随机III期次测试：SOC1 / SGOG-OV2。

不定期：护理人员胰脏症

写作者：清华大学附属里山的医院臧荣余任教等

概要：6001

Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial.

Session: Gynecologic Cancer

Author(s): He Huang, Yanling Feng, Ting Wan, Yanna Zhang, Xinping Cao, Yongwen Huang, Ying Xiong, Xin Huang, Min Zheng, Yanfang Li, Jundong Li, Guandi Chen, Hu Li, Yile Chen, Liguo Ma, Hongying Yang, Li Li, Shuzhong Yao, Qing Liu, Jihong Liu

Abstract: 6007

IB1-IIA2期宫颈胰脏根治性阴囊切除术后常规疗法里的序贯放化学治疗对比单独放射治疗或同步放化学治疗（STARS研究成果）：一项随机、对照、新开标签的III期次测试。

开都会：护理人员胰脏症

写作者：里山大学防治里心黄鹤任教、刘继红任教等

概要号：6007

CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival ysis of the randomized phase III trial 1 ysis of the randomized phase III trial.

Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Author(s): Yi-Long Wu, Wenzhao Zhong, Qun Wang, Weimin Mao, Song-Tao Xu, Lin Wu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Xiao-Fei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Jin-Ji Yang, Hong-Hong Yan, Xue-Ning Yang, Si-yang Liu, Qing Zhou

Abstract: 9005

CTONG1104：常规吉非替尼对比化学治疗主要用途可切除的EGFR甲基化的N1-N2期NSCLC-随机III期诊断次测试的事与愿违总体肉食动物分析方法。

不定期：肺胰脏—非小蛋白质渐进-区域/小蛋白质/其他胸部

写作者：东莞市团结的医院吴一龙任教等

概要号：9005

First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332).

Session: Lung Cancer—Non-Small Cell Metastatic

Author(s): Xiaoshan Wang, Ming Zeng

Abstract: 9508

EGFR甲基化寡转移非小蛋白质肺胰脏患儿前沿酪氨酸激酶羟基协同或不协同积极前线渐进放射治疗：III期新开标签诊断随机次测试（SINDAS）的里期结果（NCT02893332）。

不定期：肺胰脏-非小蛋白质转移

写作者：四川省团结的医院曾铭任教等

概要：9508

Overall survival and biomarker ysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.

Session: Melanoma/Skin Cancers

Author(s): Xinan Sheng, Xieqiao Yan, Zhihong Chi, Lu Si, Chuanliang Cui, Bixia Tang, Siming Li, Lili Mao, BIN LIAN, Xuan Wang, Xue Bai, Li Zhou, Yan Kong, Jie Dai, Keith Flaherty, Jun Guo

Abstract: 10007

Toripalimab，一种针对就其死亡-1（PD-1）的人源化IgG4单克隆抗体协同阿昔替尼主要用途前列腺癌肺部乳癌患儿的Ib期研究成果的总肉食动物期和生物标志物分析方法。

不定期：乳癌/皮肤胰脏

写作者：北京大学的医院郭军、盛锡楠任教等

概要：10007

Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL).Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Xinxin Wang, Shiqi Li, Lei Gao, Zhongtao Yuan, Kun Wu, Lin Liu, Le Luo, Yao Liu, Cheng Zhang, Jia Liu, Chunhui Yang, Yu Li, Jiaping He, Xun Ye, Zhimin Li, Xu Tan, Jianning Ge, Wei Cao, Sanbin Wang, Xi ZhangAbstract: 3013Poster: 77 GC027的兼容性和结果：通用CAR-T蛋白质首次生理次测试疗法罹患/难治性T蛋白质急性淋巴蛋白质前列腺癌（r/r T-ALL）的兼容性和。开都会：开发设计里的疗法技术-免疫疗法。写作者：王欣欣等概要：3013剧照：77 Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Jianming Xu, Yi Li, Qingxia Fan, Yongqian Shu, Zhijun Wu, Tongjian Cui, Kangsheng Gu, Min Tao, Xiuwen Wang, Chengxu Cui, Nong Xu, Juxiang Xiao, Quanli Gao, Yunpeng Liu, Tao Zhang, Hui Zhou, Yan Wang, Linxinyu Xu, Zhuo Ma, Yanqi WangAbstract: 4511Poster: 119 信迪利单抗在中后期胃上皮细胞蛋白质胰脏患儿里的分析方法：一项随机的新开标签II期次测试（ORIENT-2）。开都会：肺肠道胰脏-肺胃胰脏、胰脏胰脏和绝道胰脏写作者：徐建明任教等概要：4511剧照：119 Eradication of medulloblastoma by NKG2D-specific CAR T-cells.Session: Central Nervous System TumorsAuthor(s): Hong-jiu Dai, Bin Sun, Dong Yang, Hui Xu, Jingjing Zhu, Jia Wei, Xudong ZhaoAbstract: 2522Poster: 13 NKG2D免疫CAR-T蛋白质对炎母蛋白质瘤的根绝性疗法开都会：里枢神经系统写作者：代红久、孙斌、杨东、徐晖、邵小妹、魏佳、赵旭东概要：2522剧照。13 Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Lin Shen, Jian Li, Yanhong Deng, Weijie Zhang, Aiping Zhou, Weijian Guo, Jianwei Yang, Ying Yuan, Liangjun Zhu, Shukui Qin, Silong Xiang, Haolan Lu, John Gong, Ting Xu, Did LiuAbstract: 3021Poster: 85 Envafolimab（KN035）在中后期错配修复毛病患儿里的分析方法开都会：开发设计里的疗法学-免疫疗法写作者：沈琳任教等概要：3021剧照。85 First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Mingzhi Zhang, Lin Yang, Xiaorui Fu, Lei Zhang, Huimin Meng, Ling Li, Xin Li, Xinhua Wang, Zhenchang Sun, Hui Yu, Zhaoming Li, Feifei Nan, Yu Chang, Zhiyuan Zhou, Jiaqin Yan, Jiwei Li, Min Wang, Fengtao You, Yu-Sheng Chen, Bozhen ZhangAbstract: 3026Poster: 90 自体CD7-CART疗法罹患/难治性ACUTE淋巴蛋白质前列腺癌/淋巴瘤的首例生理诊断次测试开都会: 开发设计性疗法学-免疫疗法写作者简介：张明志，杨林等概要：3026剧照: 90 A phase Ib study of simmitecan (LP) single-agent and in combination with 5-fluorouracil/leucovorin (5-FU/LV) or thalidomide (T) in patients with advanced solid tumor.Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor BiologyAuthor(s): Jifang Gong, Ting Deng, Jie Li, Ming Lu, Jian Li, Yi Ba, Qiuqiong Yu, Lin ShenAbstract: 3523Poster: 253 萨里替康（LP）单药和5-氟尿嘧啶/白藜芦醇（5-FU/LV）或沙利度羟基（T）协同应主要用途中后期并不一定瘤患儿的Ib期研究成果开都会：发展性疗法学便是分子靶向药物和生物学写作者：龚继芳，沈琳任教等概要：3523剧照：253 A phase II study of rh-endostatin combined with paclitaxel and nedaplatin in treating patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Zhiqiang Wang, Yu-Hong Li, De-Shen Wang, Fenghua Wang, Chao Ren, Qiong TanAbstract: 4522Poster: 130 Rh-endostatin协同紫杉醇和nedaplatin疗法罹患性或前列腺癌胃上皮细胞蛋白质胰脏（ESCC）患儿的II期研究成果。开都会：肺肠道胰脏-肺胃、胰脏和绝道胰脏的研究成果写作者：王志强，郭玉红，王德申，王凤华，任超，谭琼 王志强、郭玉红、王德深、王凤华、任超、谭琼概要：4522剧照：130 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Yan Song, Ning Li, Lan Mu, Shu Zhang, Qingxia Fan, Xinjun Liang, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Jing HuangAbstract: 4524Poster: 132 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.开都会：肺肠道胰脏-肺胃胰脏、胰脏胰脏和绝管胰脏的中卫疗法写作者：宋艳等概要：4524剧照：132 A urine exosomal circRNA classifier for detection of high-grade prostate cancer at initial biopsy: A multicenter, retrospective study.Session: Genitourinary Cancer—Prostate, Testicular, and PenileAuthor(s): Liaoyuan Li, Wen Tao, Yadi He, Tao He, Qing Li, Zhenquan Wu, Weiming Deng, Lingxiao ZhangAbstract: 5522Poster: 103 一种尿液外体马蹄形RNA方差主要用途初始活检时检测高等级胰脏的尿液外体马蹄形RNA方差：一项多里心的回顾性研究成果开都会：泌尿循环系统胰脏症；还有胰脏、睾丸胰脏和胰脏写作者简介：Liaoyuan Li等概要：5522剧照。103 Adjuvant chemotherapy after concurrent chemoradiation therapy for locally advanced cervical cancer.Session: Gynecologic CancerAuthor(s): Lingna Kou, Tao Zhang, Siyun Peng, Yifei Wang, Mingyang Yuan, Minmin LiAbstract: 6031Poster: 202 渐进中后期宫颈胰脏并发化学治疗后的常规化学治疗开都会: 护理人员胰脏症写作者简介： 郭珉珉等概要：6031剧照：202 Association between calcitonin and efficacy of anlotinib in medullary thyroid carcinoma: An ysis based on the ALTER01031 trial.Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Pingzhang Tang, Zhengang Xu, Xiangqian Zheng, Dapeng Li, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6526Poster: 187 降钙素与安罗替尼疗法甲状腺炎性胰脏的相关性：基于ALTER01031次测试的分析方法。都会话里：头颈部写作者：天津市的医院高明任教概要：6526剧照。187 Influence of Eastern Cooperative Oncology Group performance status (ECOG PS), tumor size and age on patient outcomes after anlotinib treatment: A subgroup ysis based on ALTER01031 trial for medullary thyroid carcinoma (MTC).Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Xiangqian Zheng, Dapeng Li, Pingzhang Tang, Zhengang Xu, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6527Poster: 188 ECOG PS、大小不一和年龄对安洛替尼疗法后患儿结局的因素: ALTER01031的亚组分析方法开都会：头颈部写作者：天津市的医院高明任教概要：6527剧照。188 Circulating tumor DNA (ctDNA) ysis predicts recurrence following surgery in patients with stage I-IIIA non-small-cell lung cancer (NSCLC): Results of GASTO1035 and GASTO1018.Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic CancersAuthor(s): Si-Yu Wang, Ning Li, Wei Ou, Chao Cheng, Peng-Peng Kuang, Hui-Qi WuAbstract: 9023Poster: 216 ctDNA分析方法计算I-IIIA期非小蛋白质肺胰脏（NSCLC）患儿术后罹患: GASTO1035和GASTO1018的结果开都会：肺胰脏-非小蛋白质渐进-这两项/小蛋白质/小蛋白质/其他胸科胰脏症写作者：Si-Yu Wang等概要：9023剧照：216 Exon-16-skipping ERBB2 (ERBB2ΔEx16) as a novel resistance mechanism against EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).Session: Lung Cancer—Non-Small Cell MetastaticAuthor(s): Xin Zhao, Linling Jin, Man Yu, Qiuxiang Ou, Hua Bao, Xue Wu, Yang Shao, Min FanAbstract: 9528Poster: 294 ERBB2ΔEx16作为非小蛋白质肺胰脏（NSCLC）里EGFR酪氨酸激酶羟基的新型耐药有助于开都会:肺胰脏-非小蛋白质前列腺癌肺胰脏写作者简介：赵昕，金玲玲，满宇，欧青楼，华宝，薛武，杨少，范敏 赵昕、金玲玲、满宇、欧青楼、华宝、薛武、杨绍、范敏概要：9528剧照：294 Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.Session: Melanoma/Skin CancersAuthor(s): Run-Cong Nie, Shu-Qiang Yuan, Yuanfang Li, Yingbo Chen, Zhiwei ZhouAbstract: 10030Poster: 379 PD-1/PD-L1次测试里中后期乳癌总肉食动物的替代往南开都会：乳癌/皮肤胰脏写作者：聂润聪，袁书强，郭元芳，陈英波，周志伟 聂润聪、袁书强、郭元芳、陈英波、周志伟概要：10030剧照：379 A phase II study of anlotinib in treating patients with relapsed or metastatic primary malignant bone tumor.Session: SarcomaAuthor(s): Lina Tang, Xiaohui Niu, Zhen Wang, Qiqing Cai, Chongqi Tu, Zhengfu Fan, Yang YaoAbstract: 11525Poster: 413 安罗替尼疗法罹患或前列腺癌原发性恶性骨患儿的II期研究成果开都会： 溃疡写作者：唐丽娜，牛晓辉，王震，蔡启清，涂崇奇，范正福，杨瑶 唐丽娜、牛晓辉、汪直、蔡启庆、涂崇奇、范正福、杨瑶概要：11525剧照。413 Preliminary evaluate the safety and efficacy of anlotinib in advanced sarcoma patients in multi-line therapy.Session: SarcomaAuthor(s): Yao Weitao, Jiaqiang Wang, Peng Zhang, Xin Wang, Xinhui Du, Zhichao Tian, Xiaoying NiuAbstract: 11526Poster: 414 进一步赞扬安罗替尼在中后期溃疡患儿多线疗法里的兼容性和。开都会：溃疡写作者：姚伟涛，王侯强，张鹏，王欣，杜新辉，田志浩，牛晓颖 姚伟涛、王侯强、张鹏、王鑫、杜鑫辉、田志超、牛晓英概要：11526剧照：414